Alivus Life Sciences Limited (ALIVUS) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Alivus Life Sciences Limited stock ₹529, price ₹1,461, that is 63.8% below the price, quality 64 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Alivus Life Sciences Limited
ALIVUS · NSEFar too expensive (fair value 64% below the price), but solid company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range ₹340.50 – ₹1,521 · fair‑value band ₹312.89 – ₹823.12 · the ₹1,461 price screens above the ₹529.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether Alivus Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally.
Show moreShow less
It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives.
The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024.
The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Stock analysis
Alivus Life Sciences Limited (ALIVUS) currently trades at ₹1,461, while our model-based Fair Value estimate is ₹529.10, 64% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹938.05 per share, and 0 of the 26 models we run sit above the ₹1,461 price.
Bear case: the Dividend Discount group reads lowest at ₹56.48, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹312.89 (bear) to ₹823.12 (bull), the price of ₹1,461 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Alivus Life Sciences Limited reported revenue of ₹25.5B in FY2026 versus ₹20.9B in FY2022, a compound +5.1%/yr. Reported net income was ₹5.6B in FY2026, compounding +7.8%/yr from FY2022.
Key figures
Market cap ₹180B (≈ $1.9B) Small · P/E ratio 26.8 · P/S ratio 6.65 · EPS (TTM) ₹54.43 · Dividend yield 0.3% · Net margin 24.8% · Return on equity 20.2% · Return on assets (EBIT) 20.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 83 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 70% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −64%, ALIVUS screens richer than that median.
Fair Value models
All 26 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
ALIVUS screens overvalued: fair value 64% below the price. Compare with Merck KGaA →
Compare Alivus Life Sciences Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on assets by industry
- Fair value gap by industry
- Stock screener with 62 metrics
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs ALIVUS |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs ALIVUS |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs ALIVUS |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs ALIVUS |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs ALIVUS |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs ALIVUS |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs ALIVUS |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs ALIVUS |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs ALIVUS |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs ALIVUS |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Alivus Life Sciences Limited (ALIVUS) overvalued or undervalued?
What is the fair value of ALIVUS?
What is the quality score of ALIVUS?
What is the price target for Alivus Life Sciences Limited (ALIVUS)?
What is the Alivus Life Sciences Limited stock forecast for 2026?
What is the revenue of Alivus Life Sciences Limited (ALIVUS)?
Does Alivus Life Sciences Limited pay a dividend?
How much is the dividend of Alivus Life Sciences Limited (ALIVUS) and when is the ex-dividend date?
What growth is priced into Alivus Life Sciences Limited (ALIVUS)?
What discount rate (WACC) does the fair value of ALIVUS use?
What is a reverse DCF?
How much growth has Alivus Life Sciences Limited (ALIVUS) delivered so far?
How fast is the sector of Alivus Life Sciences Limited (ALIVUS) growing?
What is the free cash flow yield of Alivus Life Sciences Limited (ALIVUS)?
What is the intrinsic value of Alivus Life Sciences Limited (ALIVUS)?
Is Alivus Life Sciences Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ALIVUS?
How much is Alivus Life Sciences Limited worth?
What do the bullish and bearish scenarios say about ALIVUS?
What is the P/E ratio of ALIVUS?
How solid is the balance sheet of Alivus Life Sciences Limited (ALIVUS)?
How far is ALIVUS from its 52-week high?
Which stocks are comparable to Alivus Life Sciences Limited?
Is Alivus Life Sciences Limited stock attractive at the current price?
How is the fair value of ALIVUS calculated?
Is it still worth investing in stocks now?
What is the share price of Alivus Life Sciences Limited (ALIVUS)?
What should I pay attention to with Alivus Life Sciences Limited right now?
Key figures of Alivus Life Sciences Limited
How large is the market capitalisation of Alivus Life Sciences Limited (ALIVUS)?
What is the P/S ratio of Alivus Life Sciences Limited (ALIVUS)?
What are the earnings per share of Alivus Life Sciences Limited (ALIVUS)?
What is the dividend yield of Alivus Life Sciences Limited (ALIVUS)?
What is the net margin of Alivus Life Sciences Limited (ALIVUS)?
What is the return on equity of Alivus Life Sciences Limited (ALIVUS)?
What is the EBIT return on assets of Alivus Life Sciences Limited (ALIVUS)?
What is the operating margin of Alivus Life Sciences Limited (ALIVUS)?
How fast is revenue growing at Alivus Life Sciences Limited (ALIVUS)?
How fast are earnings growing at Alivus Life Sciences Limited (ALIVUS)?
How much net debt does Alivus Life Sciences Limited (ALIVUS) carry?
Watch Alivus Life Sciences Limited in the live analysis
One click puts Alivus Life Sciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.